The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Source link
About The Author
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics